This trend could be explained by prior exposure, as this class of antifungals had been commonly used in the past as prophylaxis in immunocompromised patients, such as those with pharmacologically induced neutropenia or HIV infection with low CD4+ lymphocyte count and we could aspect some novelty in the next future due to the changes in prophylactic strategies in some populations at high risk for invasive fungal infections [25,26]. Here, CD4 is linked to neutropenia.